Skip to content

Construction and validation of aAnalysis of Risk Factors for Hypoproteinemia in Patients with Advanced Ovarian Cancer after Surgery and Construction and Validation of Prediction Model

Construction and validation of aAnalysis of Risk Factors for Hypoproteinemia in Patients with Advanced Ovarian Cancer after Surgery and Construction and Validation of Prediction Model - Prediction model for postoperative hypoproteinemia in patients with ovarian cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122305
Enrollment
Unknown
Registered
2026-04-11
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative hypoproteinemia after ovarian cancer surgery

Interventions

Observational group:None

Sponsors

West China Second University Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old 2. Pathologically diagnosed with primary ovarian cancer (FIGO III-IV stage) 3. Received tumor cell depletion surgery (PDS or NACT-IDS) between January 2020 and June 2025 4. Serum albumin test completed within 1 week before surgery and within 72 hours after surgery 5. Complete clinical data

Exclusion criteria

Exclusion criteria: 1. Severe liver and kidney dysfunction (Child-Pugh C grade or eGFR < 30 ml/min/1.73m^2) 2. Comorbid with other active malignant tumors 3. Received total parenteral nutrition within 1 month prior to the surgery 4. Emergency surgery or palliative surgery patients 5. Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
Serum albumin level within 72 hours after surgery (ALB < 35 g/L);Preoperative nutritional status (serum albumin level, percentage of body weight loss);Inflammatory markers (C-reactive protein, CRP);Surgical factors (operation duration, blood loss, intraoperative fluid balance);Treatment regimen (neoadjuvant chemotherapy, combined organ resection);

Countries

China

Contacts

Public ContactZhu Qing

West China Second University Hospital, Sichuan University

zhuqing@scu.edu.cn+86 158 8249 9569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026